Cytek Q3 2025 net loss $5.5M; adjusted EBITDA $2.5M; revenue +2% to $52.3M

Cytek Biosciences, Inc.

Total revenue $52.3M, +2% YoY; installed base 3,456 instruments (+161 units in Q3).
GAAP net loss $5.5M vs net income $0.9M in Q3 2024; GAAP gross margin 53% vs 56%.
Adjusted EBITDA $2.5M vs $7.6M in prior year; ex-investment income $0.5M vs $5.7M.
Recurring revenue up 19% YoY; biopharma/CRO revenue up 14% YoY.
FY2025 revenue guidance reaffirmed $196M-$205M (-2% to +2% growth).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.